A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of Low Dose MN rsgp120/HIV-1 (Genentech) in Combination With QS21 Adjuvant or Alum in Healthy Adults
PHASE1CompletedINTERVENTIONAL
Enrollment
37
Participants
Timeline
Start Date
Not specified
Study Completion Date
January 31, 1999
Conditions
HIV Infections
Interventions
BIOLOGICAL
rgp120/HIV-1MN
Trial Locations (3)
14642
Univ. of Rochester AVEG, Rochester
35294
UAB AVEG, Birmingham
98144
UW - Seattle AVEG, Seattle
All Listed Sponsors
lead
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
NCT00000853 - A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of Low Dose MN rsgp120/HIV-1 (Genentech) in Combination With QS21 Adjuvant or Alum in Healthy Adults | Biotech Hunter | Biotech Hunter